Press Conference Announcing the Marketing of Aidea Pharma’s New Anti-HIV/AIDS Innovative Products
On April 25th, 2023, Jiangsu Aidea Pharmaceutical Co., LTD (referred to as Aidea Pharma) held a new product launching press conference successfully for Ainuovirine Tablets and Ainuomiti Tablets in Yangzhou, China. Aidea Pharma announced the clinical progress of Ainuovirine Tablets, the first oral anti-HIV/AIDS new drug with independent intellectual property rights in China, and the three-in-one compound formulation Ainuomiti Tablets. As a leading enterprise in anti-HIV new drug R&D in China, the new drug launch conference attracted many government officials, leaders of Center for Disease Control and Prevention, well-known experts, industry insiders and investment institutions to attend to jointly discuss the latest information of HIV/AIDS prevention in China and even the world to contribute wisdom and strength for antiviral treatment.
Jinjian Wang, the Party Secretary of Yangzhou Municipal Committee, on behalf of the CPC Yangzhou Municipal Committee and Yangzhou Municipal People’s Government, expressed warm congratulations on the launch of the new drugs of Aidea Pharma in his speech, and expressed his heartfelt thanks to people from all walks of life who have been concerned about the development of Yangzhou's biomedical industry for a long time. Secretary Wang said that through the efforts in recent years, Yangzhou's biomedical industry has started from scratch, from small to large, and the industrial foundation has been continuously consolidated, with a good momentum of industrial development. He has high hopes for the future of Aidea Pharma, hoping that this kind of medical development can promote Yangzhou's economic development and attract more national enterprises to be deeply rooted in this vast land.
"The launch of Aidea Pharma's new drugs is like a seed, and sets a milestone of drug R&D in China." Academician Jun Chen of the Chinese Academy of Sciences believed that the launch of Aidea Pharma’s Ainuovirine Tablets and Ainuomiti Tablets is not only the fruit of Aidea Pharma’s continuous research, development and innovation in anti-HIV/AIDS drugs, but also the representative achievement of the National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the 13th Five-Year Plan period, which is of extraordinary significance to the 1.22 million AIDS patients across China. As academician Jun Chen said, the launch of two anti-HIV new drugs is not only a milestone, but also a major victory in the field of HIV/AIDS prevention and control in "Healthy China" construction.
Yang Hao, the president of the Chinese Association of STD and AIDS Prevention and Control (CASAPC), also pointed out in his speech that in the past 20 years, China’s anti-HIV/AIDS drugs have changed from unavailable to expensive imported drugs, and then domestic generic drugs to today's domestic innovative new drugs with independent intellectual property rights. It is the result of the joint efforts of various pharmaceutical enterprises, experts and scholars. The president Yang Hao said that Aidea Pharma has always combined the development of the company with the needs of our country and society. As the first scientific and innovative enterprise to participate in the "Collection of Real-World Data (RWD) on HIV/AIDS Clinical Diagnosis and Treatment" project initiated by the CASAPC, Aidea Pharma has launched Ainuovirine Tablets and Ainuomiti Tablets with its own scientific research strength to meet the treatment needs of patients through innovative high-quality drugs. He hoped that Aidea Pharma can continue to deepen its efforts in the field of anti-HIV/AIDS and actively participate in the public welfare projects initiated by the CASAPC, and make contributions to the improvement of the comprehensive treatment ability of HIV/AIDS in China.
Dr. Heliang Fu, the chairman of Aidea Pharma, introduced the independent research and development process and exploration path of the two new drugs. When referring to the English name of Aidea Pharma, Dr. Fu Heliang interpreted it as "Leading Innovation and Dreams". With the strong support of the government and the concerted efforts of many domestic clinical experts, the company quickly decided the strategic direction at the beginning of its establishment, built a set of unique innovation system, and constantly overcame difficulties, finally developed two anti-HIV/AIDS new drugs with independent intellectual property rights. The two new drugs have won the support of the National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the 13th Five-Year Plan period. Dr. Heliang Fu sincerely hoped that, as a domestic pharmaceutical company, Aidea Pharma can work together with experts from all walks of life to develop more innovative new drugs like Ainuovirine Tablets and Ainuomiti Tablets for patients in China and even the world, and bring the light of hope to those patients.
Afterwards, the exciting launch ceremony of Ainuovirine Tablets and Ainuomiti Tablets was held on the spot, where the participants jointly celebrated the glorious release of the two new drugs. With the enterprise philosophy of "Greatest kindness is like water." and the R&D attitude of "Striving to develop innovative products for HIV/AIDS infectors", it is believed that the two new drugs can create a more promising prospect in the field of HIV/AIDS treatment and benefit a wider range of AIDS patients.
During the academic report session, Professor Hao Wu, the director of Beijing You’an Hospital, Capital Medical University, reported the phase Ⅲ clinical data of Ainouvirine Tablets. Professor Hao Wu emphasized that the Phase Ⅲ clinical trial of Ainuovirine Tablets was of high quality, and its antiviral efficacy was reliable at 96 weeks. It is better than Efavirenz regimen in improving the trend of immune reconstitution and in the safety of neuropsychiatric system, blood lipid metabolism and liver function. In addition, Ainuovirine Tablets are not metabolized by CYP3A in the body, so the risk of drug-drug interaction is less. The results of this clinical trial have been published in The Lancet Regional Health - Western Pacific, an authoritative international medical journal. It is the first time that China's innovative oral anti-HIV/AIDS drug has introduced in the top international clinical medical journal.
Professor Fujie Zhang from Beijing Ditan Hospital, Capital Medical University introduced the progress of the phase III clinical trial of Ainuomiti Tablets. Professor Fujie Zhang said that the design of Phase III clinical trial of Ainuomiti Tablets complied with the international standards of similar clinical trials, and the drop-out rate of the 48-week visit was less than 1%. As a three-in-one single-tablet compound formulation with independent intellectual property rights in China, Ainuomiti Tablets have significantly improved patient compliance and brought therapeutic benefits to more patients.
Professor Weiping Cai, the chief physician of the Eighth People’s Hospital, Guangzhou Medical University, reported the real-world data analysis of Ainuovirine Tablets. Based on the analysis of real-world data, it was found that the Ainuovirine Tablets regimen had ideal virus inhibition and a good trend of immune reconstruction in the initial and treated patients. In terms of safety, Ainuovirine Tablets have the obvious advantages of being friendly to blood lipids, effective improvement of blood sugar, and having a low risk of liver damage.
Professor Yiming Shao, the chief expert and researcher in the field of anti-HIV/AIDS of the Chinese Center for Disease Control and Prevention, presided over the above academic report session. Professor Shao said that the successful approval of Ainuomiti Tablets filled the gap of anti-HIV/AIDS new drugs in China, which is conducive to improving patients’ long-term treatment compliance. Therefore, he is full of expectations for the disclosure of the results of the Phase III clinical trial of Ainuomiti Tablets. Moreover, he would like to thank the R&D personnels of the new drugs from Aidea Pharma and clinical experts for bringing a new generation of safe and effective anti-HIV/AIDS "Chinese regimen" to the vast number of HIV infectors in China.
Scientific research is encouraging, and drug development is in full swing. Academician Wang Guangji of the Chinese Academy of Engineering highly affirmed Aidea Pharma’s continuous independent research and development in his closing speech. He believed that the launch of the anti-HIV innovative new drugs - Ainuovirine Tablets and Ainuomiti Tablets, not only broke the "stuck neck" problem in the field of major infectious diseases, but also provided a new choice for HIV infectors in China to keep pace with the international community.
With the successful convening of the press conference of Ainuovirine Tablets and Ainuomiti Tablets in China, it marks that Aidea Pharma has left a mark in the history of the development of domestic anti-HIV/AIDS new drugs, and it has also pointed out the independent R&D direction of drug innovation. The domestic enterprises represented by Aidea Pharma have taken solid and powerful steps to make uninterrupted efforts and explorations. With this strength, it will promote the pharmaceutical industry to achieve a steady development and accelerate the transformation of our country from a pharmaceutical major country to a leading country.